Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH

Clinical therapeutics1 May 2008Cited by 37 (Europe PMC)

PMID18555933DOI10.1016/j.clinthera.2008.05.004PepBankPUB-18555933

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced 24-hour time-average glucose compared with placebo.
In plain wordsIn people with diabetes, exenatide reduced average daily blood sugar compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
Decrease24-hour time-average glucose
Study
n = 30
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Measurements
Time-average glucose
7 mmol/L
exenatide
Time-average glucose
8.8 mmol/L
placebo
Source sentences
Summary
After 2 weeks (study end), the 24-hour time-average glucose values were 7.0 (0.2) and 8.8 (0.3) mmol/L for exenatide-treated and placebo-administered patients, respectively (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593301
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced glucose two hours after the morning meal compared with placebo.
In plain wordsIn people with diabetes, exenatide reduced blood sugar after breakfast compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose two hours after morning meal
Study
n = 30
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Measurements
Post-meal glucose
6.6 mmol/L
exenatide, morning
Post-meal glucose
12 mmol/L
placebo, morning
Source sentences
Summary
The glucose values for patients treated with exenatide were lower compared with those in patients who received placebo 2 hours after the morning meal (6.6 [0.4] vs 12.0 [0.5] mmol/L; P < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593302
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced glucose two hours after the midday meal compared with placebo.
In plain wordsIn people with diabetes, exenatide reduced blood sugar after lunch compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose two hours after midday meal
Study
n = 30
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Measurements
Post-meal glucose
8.8 mmol/L
exenatide, midday
Post-meal glucose
11.8 mmol/L
placebo, midday
Source sentences
Summary
The glucose values for patients treated with exenatide were lower compared with those in patients who received placebo 2 hours after the morning meal (6.6 [0.4] vs 12.0 [0.5] mmol/L; P < 0.001), the midday meal (8.8 [0.5] vs 11.8 [0.6] mmol/L; P = 0.001), and the evening meal (6.8 [0.4] vs 11.3 [0.4…
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593303
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced glucose two hours after the evening meal compared with placebo.
In plain wordsIn people with diabetes, exenatide reduced blood sugar after dinner compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose two hours after evening meal
Study
n = 30
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Measurements
Post-meal glucose
6.8 mmol/L
exenatide, evening
Post-meal glucose
11.3 mmol/L
placebo, evening
Source sentences
Summary
The glucose values for patients treated with exenatide were lower compared with those in patients who received placebo 2 hours after the morning meal (6.6 [0.4] vs 12.0 [0.5] mmol/L; P < 0.001), the midday meal (8.8 [0.5] vs 11.8 [0.6] mmol/L; P = 0.001), and the evening meal (6.8 [0.4] vs 11.3 [0.4…
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593304
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide shortened time above glucose 7.8 mmol/L compared with placebo.
In plain wordsIn people with diabetes, exenatide shortened time with glucose above 7.8 mmol/L compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTime above glucose 7.8 mmol/L
Study
n = 30
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Measurements
Time above threshold
6.8 hours
exenatide
Time above threshold
14.1 hours
placebo
Source sentences
Summary
The mean durations of patient exposure to glucose concentrations >7.8 and >11.1 mmol/L were significantly shorter for the exenatide group compared with the placebo group (>7.8 mmol/L: 6.8 [0.9] vs 14.1 [1.1] hours; >11.1 mmol/L: 1.0 [0.7] vs 4.7 [0.8] hours; both, P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593305
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide shortened time above glucose 11.1 mmol/L compared with placebo.
In plain wordsIn people with diabetes, exenatide shortened time with glucose above 11.1 mmol/L compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTime above glucose 11.1 mmol/L
Study
n = 30
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Measurements
Time above threshold
1 hours
exenatide
Time above threshold
4.7 hours
placebo
Source sentences
Summary
The mean durations of patient exposure to glucose concentrations >7.8 and >11.1 mmol/L were significantly shorter for the exenatide group compared with the placebo group (>7.8 mmol/L: 6.8 [0.9] vs 14.1 [1.1] hours; >11.1 mmol/L: 1.0 [0.7] vs 4.7 [0.8] hours; both, P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593306
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced postprandial triglyceride excursions after the morning and evening meals compared with placebo.
In plain wordsIn people with diabetes, exenatide reduced triglyceride rises after breakfast and dinner compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial triglyceride excursions after morning and evening meals
Study
n = 30
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
After 2 weeks, the postprandial triglyceride excursions after the morning and evening meals for patients treated with exenatide were significantly lower compared with those treated with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593307
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide had no apparent effect on free fatty acid concentrations compared with placebo.
In plain wordsIn people with diabetes, exenatide had no apparent effect on free fatty acids compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFree fatty acid concentrations
Study
n = 30
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
5 microg BID for 1 week, then 10 microg BID for the next week · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
There was no apparent effect on free fatty acid concentrations.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD.
Summary · context
Following the baseline admission, patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days.
Report a problemFND-1855593309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.